Maternal antenatal methylxanthine (including caffeine) treatment for improving preterm outcomes

Files in this item

Files Size Format View
By request of the author, access to this item is restricted. See below for more details.

Maternal antenatal methylxanthine (including caffeine) treatment for improving preterm outcomes

Roehr, Charles Christoph C.; Banerjee, Rupjani; Alarcon-Allen, Ana; Dempsey, Eugene M.
Date: 2019-02-25
Copyright: © 2019, the Cochrane Collaboration. Published by John Wiley & Sons, Ltd. All rights reserved.
Related: https://doi.org//10.1002/14651858.CD013275
Full text restriction information: Access to this article is restricted until 12 months after publication by request of the publisher.
Restriction lift date: 2020-02-25
Citation: Roehr, C. C. C., Banerjee, R., Alarcon-Allen, A. and Dempsey, E. (2019) 'Maternal antenatal methylxanthine (including caffeine) treatment for improving preterm outcomes', Cochrane Database of Systematic Reviews, Issue 2, CD013275 (9pp). doi: 10.1002/14651858.CD013275
Published Version: 10.1002/14651858.CD013275

Abstract:

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To review and summarise the existing evidence of the relationship between maternal methylxanthine (including caffeine) consumption (or by any other method of administration) versus no intervention, placebo or a different methylxanthine, before birth with the intention to influence outcomes in preterm newborns, with particular focus on cardiorespiratory adaptation at birth and long-term neurodevelopmental outcomes.

Show full item record

This item appears in the following Collection(s)

This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement